ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADC Therapeutics posts robust Q4 results, eyes pipeline expansion

ADC Therapeutics delivered strong financial results, bolstered by Zynlonta's sales growth and a healthy cash position.
Strategic decisions on pipeline programs and market access initiatives demonstrate a focus on long-term growth and profitability.
While facing challenges such as market access delays and community adoption hurdles, ADC Therapeutics remains poised for success with multiple growth opportunities ahead.

ADC Therapeutics accelerates pipeline progress and optimizes ZYNLONTA's potential

ADC Therapeutics is making strides in pipeline prioritization and operational efficiencies, focusing on ZYNLONTA's commercial success.
The company faces challenges in navigating market dynamics and implementing strategic changes while capitalizing on growth opportunities.
Opportunities lie in expanding trial sites, exploring potent combinations, and leveraging the new go-to-market model for enhanced performance.
Overall, ADC Therapeutics aims for sustained growth through strategic resource allocation and operational enhancements.

ADC Therapeutics reports revenue growth and strategic expansions in Q2

ADC Therapeutics showcased solid Q2 performance with revenue growth and strategic expansions.
While facing challenges in clinical trials and market dynamics, the company is leveraging strengths in portfolio investments and market positioning.
Opportunities lie in upcoming milestones, international expansions, and innovative sales strategies for sustained growth.

ADC Therapeutics reports mixed Q3 results, positive pipeline outlook

ADC Therapeutics faced challenges in ZYNLONTA sales but showcased positive pipeline updates and promising Cami trial results.
Management's focus on cost control and cash preservation aligns with maintaining financial stability until mid-2025.
Analysts' inquiries into commercial strategies and regulatory timelines reflect market interest and potential growth opportunities.
Overall, ADCT's performance highlights a mix of challenges, strengths, and opportunities in navigating the competitive landscape.

ADC Therapeutics reports robust earnings, eyes expansion in oncology market

ADC Therapeutics demonstrated strong financial performance and progress in clinical trials, positioning itself well for future growth. Strategic focus on key pipelines and real-world data strategies highlight a commitment to innovation.
While facing competition and evolving treatment landscapes, the company has opportunities to expand ZYNLONTA and leverage next-gen platforms. Ongoing partnership discussions and upcoming trial results offer avenues for advancement.
Challenges include market differentiation, safety data focus, and successful trial enrollment. Managing these hurdles while capitalizing on growth opportunities will be crucial for ADC Therapeutics' future success.

ADCT reports revenue growth and strategic advancements in Q1

ADCT's Q1 performance reflects revenue growth, cost management, and strategic investments in pipeline development and financial stability.
Strengths lie in ZYNLONTA's performance, successful fundraising, disciplined capital allocation, and diversified pipeline progress.
Challenges include market competition, net losses, regulatory considerations, and balancing expenses with revenue growth.
Opportunities arise from expanding into new indications, advancing therapeutic candidates, regulatory engagements, and solid tumor pipeline growth.

ADC Therapeutics achieves profitability driven by ZYNLONTA in hematology

ADC Therapeutics demonstrated strong financial performance with commercial profitability and cost management improvements.
The company's focus on hematology and advancements in product pipeline position them for future growth.
While facing challenges in sales variability and market competition, ADC Therapeutics has opportunities for expansion and differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ADC Therapeutics SA (NYSE:ADCT ) Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - CMO Patrick van Berkel - Chief Scientific Officer Jose Carmona - CFO Conference Call Participants Yun Zhong - Jefferies Michael Schmidt - Guggenheim Securities Unidentified Analyst - RBC Capital Markets Brian Cheng - J.P. Morgan Chase Operator Good day and thank you for standing by.

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago.

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million. The offering is expected to close on May 8, 2024, subject to customary closing conditions.

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA ®

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Officer, and Patrick van Berkel, PhD, Chief Scientific Officer, highlighting recent updates and the Company's novel exatecan-based antibody drug conjugate platform. A live question and answer session will follow the presentations.

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial for loncastuximab will determine the company's near-term aspirations and market sentiment.

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2023, and provide business updates.

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601 targeting AXL LAUSANNE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on its novel antibody drug conjugates (ADCs) have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego, CA from April 5-10, 2024. “We're excited to share compelling preclinical data supporting the future clinical development of the next-generation ADCs in our solid tumor portfolio, including those targeting Claudin-6 and NaPi2b, at the AACR Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 at 9:50 a.m. ET.

ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline

Arcellx

Viking Therapeutics

Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.

The 3 Biotech Stocks That Could Make Your February Unforgettable

Intellia Therapeutics

With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.

ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why

Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

Pfizer

The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.

Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth

LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE's noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria, as the average closing price of its common shares was below $1.00 over a consecutive 30 trading-day period. As closing price of the common shares on December 29, 2023 and the average closing price of the common shares over the 30 trading-day period ending on December 29, 2023 were both above $1.00, the deficiency was cured.

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ZYNLONTA® 1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023

ADC Therapeutics Provides Business Updates

ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. New data shows that the combination of Zynlonta and Rituximab can cure certain types of lymphoma, and ADCT has a robust pipeline of potential therapies.

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate

ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

News for ADC Therapeutics Stock (ADCT)